Therapeutic agents for steroid-refractory immune checkpoint inhibitor-related myocarditis: a narrative review.

The pathogenesis of steroid-refractory IRM and the treatment regimen remain unclear. A large number of studies need to be conducted to validate or update our proposed treatment approach.